161 related articles for article (PubMed ID: 35414481)
21. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.
Konings IC; Harinck F; Poley JW; Aalfs CM; van Rens A; Krak NC; Wagner A; Nio CY; Sijmons RH; van Dullemen HM; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ;
Pancreas; 2017 Jan; 46(1):28-34. PubMed ID: 27846136
[TBL] [Abstract][Full Text] [Related]
22. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
23. [Pancreatic cancer-screening or surveillance?].
Sirtl S; Vornhülz M; Hofmann FO; Mayerle J; Beyer G
Radiologie (Heidelb); 2023 Dec; 63(12):908-915. PubMed ID: 37878016
[TBL] [Abstract][Full Text] [Related]
24. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
[TBL] [Abstract][Full Text] [Related]
25. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer.
Hofmann BT; Stehr A; Dohrmann T; Güngör C; Herich L; Hiller J; Harder S; Ewald F; Gebauer F; Tachezy M; Precht C; Izbicki JR; Bockhorn M; Wagener C; Wolters-Eisfeld G
Clin Cancer Res; 2014 Dec; 20(23):6117-26. PubMed ID: 25320359
[TBL] [Abstract][Full Text] [Related]
26. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
27. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study.
Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
Scand J Gastroenterol; 2021 Aug; 56(8):965-971. PubMed ID: 34165379
[TBL] [Abstract][Full Text] [Related]
28. Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer.
Majumder S; Taylor WR; Foote PH; Gysbers BJ; Cao X; Mahoney DW; Burger KN; Doering KA; Graham RP; Couch FJ; Petersen GM; Kisiel JB
Pancreatology; 2022 Sep; 22(6):770-773. PubMed ID: 35843766
[TBL] [Abstract][Full Text] [Related]
29. Serum biomarker panels for the detection of pancreatic cancer.
Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
[TBL] [Abstract][Full Text] [Related]
30. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program.
Vasen HFA; Boekestijn B; Ibrahim IS; Inderson A; Bonsing BA; de Vos Tot Nederveen Cappel WH; Feshtali S; Wasser MN
HPB (Oxford); 2019 Oct; 21(10):1371-1375. PubMed ID: 30910317
[TBL] [Abstract][Full Text] [Related]
31. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
32. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.
Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F;
Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.
Ibrahim IS; Vasen HFA; Wasser MNJM; Feshtali S; Bonsing BA; Morreau H; Inderson A; de Vos Tot Nederveen Cappel WH; van den Hout WB
United European Gastroenterol J; 2023 Mar; 11(2):163-170. PubMed ID: 36785917
[TBL] [Abstract][Full Text] [Related]
34. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
35. Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.
Peters MLB; Eckel A; Lietz A; Seguin C; Mueller P; Hur C; Pandharipande PV
Pancreatology; 2022 Sep; 22(6):760-769. PubMed ID: 35752568
[TBL] [Abstract][Full Text] [Related]
36. Quantitative structural analysis of glycans expressed within tumors derived from pancreatic cancer patient-derived xenograft mouse models.
Hasehira K; Furuta T; Shimomura O; Asada M; Oda T; Tateno H
Biochem Biophys Res Commun; 2021 Jan; 534():310-316. PubMed ID: 33288196
[TBL] [Abstract][Full Text] [Related]
37. Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.
Chittenden A; Haraldsdottir S; Chen E; Nissim S
Hematol Oncol Clin North Am; 2022 Oct; 36(5):943-960. PubMed ID: 36265992
[TBL] [Abstract][Full Text] [Related]
38. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis.
Klatte DCF; Boekestijn B; Onnekink AM; Dekker FW; van der Geest LG; Wasser MNJM; Feshtali S; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME;
Gastroenterology; 2023 Jun; 164(7):1223-1231.e4. PubMed ID: 36889551
[TBL] [Abstract][Full Text] [Related]
39. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
40. Short report - Lethal and aggressive pancreatic cancer: molecular pathogenesis, cellular heterogeneity, and biomarkers of pancreatic ductal adenocarcinoma.
Kannan S; Shaik Syed Ali P; Sheeza A
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):1017-1019. PubMed ID: 35179767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
